(file opens in new tab)
Phosphatidylserine Clinical Studies
"Analysis of clinical subgroups suggested that persons within the sample who performed at a relatively low level prior to treatment were most likely to respond to BCPS. Within this subgroup, there was improvement on both computerized and standard neuropsychological performance tests, and also on clinical global ratings of improvement. The results suggest that the compound may be a promising candidate for treating memory loss in later life. "
[T.H. Crook et al., Effects of phosphatidylserine in ageassociated memory impairment, Neurology May 1991 vol. 41 no. 5 644-649]
"The application of the computerized EEG method DYNAMIC BRAIN MAPPING (HZI Research Center, Tarrytown, New York) is able to proof the therapeutic effect of Phosphatidylserine: the acceleration of a slowed EEG in Parkinsonian patients with SDAT."
[EW Fungfgeld et al., Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT), Progress in Clinical and Biological Research, 1989, 317:1235-1246]
"Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo. Differences between treatment groups were most apparent among patients with less severe cognitive impairment. Results suggest that phosphatidylserine may be a promising candidate for study in the early stages of AD."
[T. Crook et al., Effects of phosphatidylserine in Alzheimer's disease,Psychopharmacology Bulletin, 1992, 28(1):61-66]